Revance Therapeutics Inc (NASDAQ:RVNC)
| 30.46 Delayed Data As of May 26 |  -0.35 / -1.14%Today’s Change | 11.27 Today|||52-Week Range 37.98 | +65.01% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Assets | Cash | 201.7M | 63.5M | 282.9M | 73.3M | |
| Short Term Investment Cash | 30.6M | -138.0M | 219.4M | -209.5M | ||
| Cash & Short Term Investments | 252.3M | 185.5M | 282.9M | 175.8M | ||
| Receivables | Receivables | 158.0K | 6.0M | 48.0K | 27.0M | |
| Inventories | Inventories | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Current Assets | Prepaid Expenses | 1.2M | 978.0K | 1.8M | -- | |
| Other Current Assets | 267.0K | 163.0K | 444.0K | 5.1M | ||
| Current Assets | 254.0M | 192.7M | 285.2M | 207.9M | ||
| Total Assets | Property, Plant and Equipment - Gross | 31.2M | 22.7M | 22.8M | 28.4M | |
| Depreciation | -11.5M | -12.2M | -13.5M | -14.0M | ||
| Other Assets | 0.00 | 500.0K | 658.0K | 3.2M | ||
| Total Assets | 275.8M | 204.4M | 295.7M | 226.3M | ||
| Liabilities | Accounts Payable | 2.7M | 3.8M | 6.8M | 8.4M | |
| Short Term Debt | 3.1M | 3.5M | 1.9M | 0.00 | ||
| Accrued Expenses | 2.0M | 7.9M | 3.7M | 5.3M | ||
| Other Current Liabilities | 3.0M | 8.6M | 4.7M | 14.5M | ||
| Other Liabilities | 12.0M | 19.6M | 20.9M | 32.0M | ||
| Total Liabilities | Long Term Debt | 5.3M | 1.9M | 0.00 | 0.00 | |
| Other Liabilities | 1.4M | 5.8M | 6.0M | 6.1M | ||
| Total Liabilities | 22.6M | 27.3M | 26.9M | 80.7M | ||
| Equity | Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Preferred Stock | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Equity | 253.3M | 177.1M | 268.8M | 145.6M | ||
| Total Shareholder Equity | 253.3M | 177.1M | 268.8M | 145.6M | ||
| Share Information | Common Shares Outstanding | 28.3M | 28.6M | 36.5M | 37.0M | |
| Addtl. Info. | No data currently available for this section. | |||||
